Sponsorship | In 2023, TSF sponsored 10 manuscripts published in Frontiers in Neurology. We have had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of The Sumaira Foundation.
Aim I | Determine the frequency of misdiagnosis of NMOSD patients as MS, and the point prevalence of misdiagnosis in different geographic census regions
Aim II | Identify the frequency of utilization of FDA-approved MS therapies in misdiagnosed NMOSD patients
Aim III | Understand the cost of misdiagnosis of NMOSD patients
Institution | Charité – Universitätsmedizin Berlin (Germany)
Aim I | To investigate the involvement of inflammasome in NMOSD, by detecting pyroptosis and the inflammasome effector cytokine IL1β in microglia-mediated astrocytic damage by AQP4-IgG
Aim II | To study whether inhibition of inflammasome and its effectors may protect astrocytes from inflammasome-mediated damage
Aim | To better understand the interplay of genetics, metabolics, and other non-genetic factors that relate to NMOSD/MOGAD patient outcomes, including quality of life.
Aim I | To compare retinal vascular plexus densities between eyes with a history of optic neuritis from people with NMOSD, MOGAD, MS and controls
Aim II | To compare retinal vascular plexus densities between eyes without a history of optic neuritis from patients with NMOSD, MOGAD, MS and controls
Aim III | To assess correlations of retinal vascular plexus densities with visual function in NMOSD, MOGAD and MS eyes
Aim | To depict the impact of neuromyelitis optica spectrum disorder (NMOSD) on employment, job loss, and work hours in a multi-country prospective survey-based study of people living with NMOSD
Aim I | Develop longitudinal database and biorepository for MOG Antibody Disease (MOGAD) patients at the Stanford Neuroimmunology Center, including multi-center collaboration. Demographic, clinical outcomes, biochemical (including MOG-IgG serial titers, presence of co-neuronal antibodies), neuroimaging and neuropsychological outcomes, when available.
Aim II | To determine if MOG IgG positivity or titer predicts index event severity or relapse
Aim III | To correlate MOG IgG serostatus with serum and cerebrospinal fluid (CSF) immune profiles (pleocytosis, oligoclonal bands, paired serum/CSF IL-6, TNF-alpha, T and B lymphocyte profiles) to inform immunopathogenesis and treatment
Aim | The overall goals of this study are to better understand the effects of the SARS-CoV-2 pandemic and COVID-19 in our population of patients with NMOSD.
Aim I | To describe the epidemiologic characteristics of all patients who carry a diagnosis of NMOSD within the Department of Defense/Defense Medical Surveillance System (DMSS).
Aim II | To confirm the presence of Aquaporin-4 and MOG autoantibodies in pre-symptomatic NMO samples.
Aim | To pilot a novel point-of-care dry blood spot diagnostic test for patients with aquaporin 4-antibody (AQP4) seropositive neuromyelitis optica spectrum disorder (NMOSD).
Aim | To evaluate the effect of different disease modifying treatments on attack and disability prevention in children with neuromyelitis optica spectrum disorder.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By continuing to use our website, you consent to the use of all the cookies. Read our privacy policy here.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
WARNING: Internet Explorer does not support modern web standards. This site may not function
correctly on this browser and is best viewed on
Chrome,
Firefox
or Edge
browsers.
Learn More.
